Clinical Trial: MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Share this article:
Clinical Trial: MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Sponsor and Collaborators

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Principal Investigator
Eric Jonasch, MD M.D. Anderson Cancer Center

ClinicalTrials.gov Identifier

NCT01239342
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Kidney Cancer Clinical Trials

Clinical Trial: Phase II Study of Vandetanib in Individuals With Kidney Cancer

Clinical trial focusing on vandetanib and kidney cancer. Phase II Study of Vandetanib in Individuals With Kidney Cancer

Clinical Trial: Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients ...

Clinical trial focusing on surgery after sunitinib malate in metastatic kidney cancer patients. Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME)

Clinical Trial: Serum CA9 Level as Biological Marker of the Treatment Response ...

Clinical trial focusing on Serum CA9 level and metastatic renal cell cancer. Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (CA9CRM)